Figure S1. PDIA1 and HLA-G mRNA levels in breast cancer patients. (A and C) PDIA1 and (B and D) HLA-G mRNA levels in (A and B) ERα-positive and (C and D) ERα-negative breast cancer patients at different stages of the disease.

A — ERα positive patients (PDI mRNA z-score)

	Stage 1	Stage 2	Stage 3	Stage 4
n	387	615	68	9
High PDI	63	130	15	2
Low PDI	324	458	53	7

B — ERα positive patients (HLA-G mRNA z-score)

	Stage 1	Stage 2	Stage 3	Stage 4
n	387	615	68	9
High HLA-G	74	124	16	1
Low HLA-G	313	491	52	8

C — ERα negative patients (PDI mRNA z-score)

	Stage 1	Stage 2	Stage 3
n	88	185	47
High PDI	37	83	16
Low PDI	51	102	31

D — ERα negative patients (HLA-G mRNA z-score)

	Stage 1	Stage 2	Stage 3
n	88	185	47
High HLA-G	40	89	19
Low HLA-G	48	96	28

Figure S2. Correlation between PDIA1 and HLA-G mRNA levels in ERα positive and ERα negative breast cancer patients at different stages of the disease. Correlation of the numbers of ERα positive (A, B and C) or ERα negative (D, E and F) breast cancer patients expressing high or low PDIA1 mRNA levels with those of HLA-G mRNA at stage 1 (A and D), stage 2 (B and E) and stage 3 (C and F). *P<0.05 and **P<0.01.

A ERα positive patients: Stage 1

	Low PDI	High PDI
n	324	63
High HLA-G	60	15
Low HLA-G	264	48

B ERα positive patients: Stage 2

	Low PDI	High PDI
n	485	130
High HLA-G	86	38
Low HLA-G	399	92

C ERα positive patients: Stage 3

	Low PDI	High PDI
n	53	15
High HLA-G	15	1
Low HLA-G	18	14

D ERα negative patients: Stage 1

	Low PDI	High PDI
n	51	37
High HLA-G	24	16
Low HLA-G	27	21

E ERα negative patients: Stage 2

	Low PDI	High PDI
n	102	83
High HLA-G	57	32
Low HLA-G	45	51

F ERα negative patients: Stage 3

	Low PDI	High PDI
n	31	16
High HLA-G	13	6
Low HLA-G	18	10